CN106822389A - A kind of pharmaceutical composition for preventing and treating ovarian cyst - Google Patents

A kind of pharmaceutical composition for preventing and treating ovarian cyst Download PDF

Info

Publication number
CN106822389A
CN106822389A CN201611132912.XA CN201611132912A CN106822389A CN 106822389 A CN106822389 A CN 106822389A CN 201611132912 A CN201611132912 A CN 201611132912A CN 106822389 A CN106822389 A CN 106822389A
Authority
CN
China
Prior art keywords
ethanol
weight portion
weight
pharmaceutical composition
percent concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201611132912.XA
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Haoyu Qingtian Medicine Technology Co ltd
Original Assignee
Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Haoyu Qingtian Medicine Technology Co ltd filed Critical Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority to CN201611132912.XA priority Critical patent/CN106822389A/en
Publication of CN106822389A publication Critical patent/CN106822389A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Pharmaceutical composition of ovarian cyst and preparation method thereof is prevented and treated the invention discloses a kind of, pharmaceutical composition of the present invention is with Chinese Lady Fern, three-jaw gold dragon, globe amaranth, mesembranone, capillarisin, β irisones as bulk drug, proportioning is formed, routinely various formulations can be made by preparation process, prevent and treat ovarian cyst evident in efficacy.

Description

A kind of pharmaceutical composition for preventing and treating ovarian cyst
Technical field
The invention belongs to technical field of traditional Chinese medicines, more particularly to a kind of pharmaceutical composition for preventing and treating ovarian cyst and its preparation side Method.
Background technology
Ovarian cyst is gynaecology's common disease, is mainly in women at fertile age.Tumour is typically small at the initial stage of a disease, clinically Non-evident sympton, could find when having only through laparotomy exploration or gynecologial examination, more in benign, with the growth of tumour, it may appear that Abdominal distension sense or lower abdomen are uncomfortable, and to a certain extent, tumour is it may happen that the complication such as rupture, torsion of pedicle and infection, gives for increase Patient brings pain.The tumour larger for volume, treatment advocates surgical removal, but has many patients to be selected because of fear operation Select expectant treatment.Ovarian cyst is relevant with endocrine factors, though ovary is small, be produce ovum and ovulate, balance it is endocrine Vitals.Ovarian cyst is mainly in the endocrine vigorous childbearing age, therefore relevant with human endocrine system, can secrete various Hormone and nervous system adjust metabolism and the physiological function of human body together.TAM is the estrogen antagonist of nonsteroidal, ERs can be competed with estrogen, and play estrogenic antagonist.Modern medicine is also believed that ovarian cyst and chronic inflammation It is relevant, therefore use antibiotic therapy.Ovarian cyst says from the angle of the traditional Chinese medical science, " abdominal mass " " accumulation " category is belonged to, more by diseases caused by external factors The six external factors which cause diseases, internal damage by the excessive seven emotions causes wet turbid fluid-retention and blood stasis retardance vessels of the uterus, with the passing of time fights and forms block.Treatment mainly disappeared with promoting blood circulation and removing blood stasis, softening hard masses, Based on clearing heat and detoxicating.
Chinese Lady Fern：It is the root of Athyriaceae Athyrium plant Chinese Lady Fern Athyrium sinense Rupr. Stem.The 7-9 months harvest, and remove fibrous root, clean, and dry.【Nature and flavor】Slight bitter；It is cool.【Return through】Lung；Large intestine channel.【Indication】Heat-clearing Removing toxic substances；Expelling parasite.For preventing and treating influenza；Measles；Encephalitis；Epidemic meningitis；Hookworm disease；Roundworm disease.【Original shape state】Plant 35-60cm high.Root Stem is short and oblique ascension, the close big scale by brown brown, lanceolar and ovum shape lanceolar full edge in top.Leafage gives birth to；Petiole 20- long 25cm, deep straw color is expanded, downward taper together with rachis and pinna rachis by small scale, base portion is dredged；Blade herbaceous stem, Glabrous, Oval lanceolar, 25-35cm long, 12-15cm wide, bottom is slightly narrow, along having a small number of glandular hairs, three times plumage splits below pinna rachis；Sliver is about 20 pairs or more, alternate, obliquely, and nearly stockless, narrow lanceolar, base portion 2-3 is to slightly shortening, and the accessory pinna 7-10cm long at middle part is wide About 3mm, blunt nosed, edge is shallow to be cleaved into jagged sliver, and small to split on tiltedly, tip has micro- tooth, and base portion is connected with narrow wing；Vein is splitting 2-3 forks, stretch up to increment on piece.Sporangiorus is elongated or short-term shape, is less crotch shape, is born in the bottom of sliver upside scun, There is 1 per sliver；Indusium and sorus similar shape, shape is eroded at brown, film quality, edge.Record in dictionary of medicinal plant.
Three-jaw gold dragon：It is Vitaceae Parthenocissus plant parthenocissus himalayana Plancs Parthenocissus himalayana （Royle）Planch. the complete stool of ［ Ampelopsis himalayana Royle ］.Autumn, winter harvesting root and stem, cut after cleaning Piece or segment, dry.Summer, autumn picking leaves, dry.【Nature and flavor】It is pungent；Temperature.【Indication】Dispelling wind and eliminating dampness；Dissipate blood stasis and smoothing collaterals.Main wind Arthritis with fixed pain caused by dampness is bitterly；Traumatic injury；Fracture.【Former phytomorph】Parthenocissus himalayana Plancs fallen leaves woody climber.Multi-branched, branch is sturdy, drabon Color；Tendril is short and branch, and there is sucker on top.The leaflet alternate of palmate 3；Common petiole 5-12cm long, without hair or hairiness；Blade papery, Middle leaflet is avette or width drape over one's shoulders needle-like avette, 6-12cm long, 2-7cm wide, and tip is tapering or nearly shape of tail, and base portion wedge shape, side life is small Leaf is asymmetric, tiltedly avette, compared with the middle of leaflet it is smaller, edge have substantially and the sawtooth with tip, above without hair, below or along vein There is thin pubescence；Petiolule 5-6mm long.Flower both sexes, cyme be often born in brachyplast top or with leaf opposite；Bennet is compared with petiole It is short；Flower light green, 5 numbers 4 are counted sometimes；Calyx shallow disc shape, full edge；Petal Long Circle；Stamen and petal opposite；Floral disc is not obvious； Style short cylindrical shape, tip often expands discoid after petal comes off.Berry is spherical, ripe time-varying dark brown, has white powder, seed 1-2 .Record in dictionary of medicinal plant.
Globe amaranth：This product is the dry capitulum of Gorgon euryale section plant globe amaranth Gomphrena globosa L..Autumn is spent Harvested when in full bloom, dried.【Nature and flavor】It is sweet, put down.【Function with cure mainly】Eliminating the phlegm, relievings asthma.For chronic bronchitis, asthmatic branch gas Guan Yan.【Proterties】This product is spherical in shape or square is circular, 1.5~2cm of diameter, rose, pink or white.Phyllary 2 is green Color, heart-shaped or avette, two masks hair, following surface is close.Flower imbricate arrangement, often spends 1 avette dry film matter shape bract of tool；Small bud Piece 2, triangular shape lanceolar, rose or white, film quality have gloss；Perianth 5, wire lanceolar, color is shallow, close long by white Pubescence；Stamen 5, filigree joint, flower pesticide micro stretching goes out；Gynoecium 1.Utricle is spherical, inside there is brown seed 1.Body is light.Gas is micro-, lightly seasoned. Record in Shanghai City Chinese medicine standard 1994 (Shanghai Health Bureau).
Mesembranone（Mesembrine）：CAS 24880-43-1, molecular formula C17H23NO3, molecular weight 289.37.【Medicine Reason is acted on】Anesthetic；Central stimulant.【Ingredient origin】Expansion mesembrianthemum Mesembryanthemum expansum, bright pine needle Chrysanthemum Mesembryanthemum anatomtcum, distortion mesembrianthemum Mesembryanthemum tortuosum.
Capillarisin（Capillarisin）：CAS 56365-38-9, molecular formula C16H12O7, molecular weight 316.26. 【Pharmacological action】Cholagogic.【Ingredient origin】Feverfew Artemisia capillaris aerial part.
Alpha, beta-lonone（Irisone）：CAS 14901-07-6, molecular formula C13H20O, molecular weight 192.30.【Biology is living Property】Spices.【Ingredient origin】Almond Prunus armeniaca, banksia rose Saussurea lappa [Syn.Aucklandia Lappa], fruit of Chinese wolfberry Lycium chinense.
3 chemical constitutions of bulk drug：
Capillarisin（Capillarisin）
Mesembranone（Mesembrine）Alpha, beta-lonone（Irisone）.
The content of the invention
The purpose of the present invention is to overcome the shortcomings of background technology, there is provided a kind of pharmaceutical composition for effectively preventing and treating ovarian cyst And preparation method thereof.
The present invention adopts the following technical scheme that realization：
The composition and weight portion for being made the bulk drug of the pharmaceutical composition for preventing and treating ovarian cyst be：
Chinese Lady Fern 4800-4900 weight portions three-jaw gold dragon 50-80 weight portion globe amaranth 3500-3700 weight portion pine needles Chrysanthemum alkali 40-70 weight portion capillarisin 100-110 weight portion alpha, beta-lonone 60-70 weight portions.
The pharmaceutical composition for preventing and treating ovarian cyst is preferably used in, is made up of the bulk drug of following weight portion：
The weight portion of 3600 weight portion mesembranone of the weight portion three-jaw of the Chinese Lady Fern 4850 imperial 65 weight portion globe amaranth of gold 60 The weight portion of 105 weight portion alpha, beta-lonone of capillarisin 65.
A kind of pharmaceutical composition for preventing and treating ovarian cyst, it is characterised in that pharmaceutical composition can be using the routine of galenic pharmacy Method prepares piece agent or capsule or dripping pill.
A kind of pharmaceutical composition for preventing and treating ovarian cyst, it is characterised in that pharmaceutical composition is constituted with chemical drugs or Chinese medicine Prevent and treat ovarian cyst medicine.
A kind of preparation method of the pharmaceutical composition for preventing and treating ovarian cyst, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：Chinese Lady Fern 4800-4900 weight portions three-jaw gold dragon 50-80 weight portions thousand days Red 3500-3700 weight portions mesembranone 40-70 weight portions capillarisin 100-110 weight portion alpha, beta-lonones 60-70 Weight portion；
Preparation method：
（1）Three-jaw gold dragon, globe amaranth, Chinese Lady Fern, mesembranone, capillarisin, β-violet are taken by bulk drug proportioning Ketone, mixes, and with the ethanol of weight percent concentration 34% as solvent, is taken in 35.5 DEG C of temperature extractions, and extraction time is 8 times, is carried every time The time is taken for 63 hours, each solvent load is 64 times of bulk drug gross weight, and filtration obtains dregs of a decoction A and extract solution A, extract solution A Ethanol is reclaimed, relative density 1.07 is concentrated into, filtered, liquid is first washed with water by H107 large pore resin absorption columns, then with again Amount percent concentration 27% ethanol solution wash-out H107 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 27% Liquid, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 47% as solvent, heating and refluxing extraction 9 times is carried every time The time is taken for 0.4 hour, each solvent load is 35 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.15 is concentrated into, filtered, liquid is first washed with water, then use by GDX-501 large pore resin absorption columns The ethanol solution of weight percent concentration 87% elutes GDX-501 large pore resin absorption columns, collects the ethanol of weight percent concentration 87% Eluent, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Preferred a kind of preparation method of the pharmaceutical composition for preventing and treating ovarian cyst, it is characterised in that make as follows It is standby：
The composition and weight portion of bulk drug be：The imperial weight of 65 weight portion globe amaranth 3600 of the weight portion three-jaw of Chinese Lady Fern 4850 gold The weight portion of 105 weight portion alpha, beta-lonone of amount part 60 weight portion capillarisin of mesembranone 65；
Preparation method：
（1）Three-jaw gold dragon, globe amaranth, Chinese Lady Fern, mesembranone, capillarisin, β-violet are taken by bulk drug proportioning Ketone, mixes, and with the ethanol of weight percent concentration 34% as solvent, is taken in 35.5 DEG C of temperature extractions, and extraction time is 8 times, is carried every time The time is taken for 63 hours, each solvent load is 64 times of bulk drug gross weight, and filtration obtains dregs of a decoction A and extract solution A, extract solution A Ethanol is reclaimed, relative density 1.07 is concentrated into, filtered, liquid is first washed with water by H107 large pore resin absorption columns, then with again Amount percent concentration 27% ethanol solution wash-out H107 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 27% Liquid, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 47% as solvent, heating and refluxing extraction 9 times is carried every time The time is taken for 0.4 hour, each solvent load is 35 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.15 is concentrated into, filtered, liquid is first washed with water, then use by GDX-501 large pore resin absorption columns The ethanol solution of weight percent concentration 87% elutes GDX-501 large pore resin absorption columns, collects the ethanol of weight percent concentration 87% Eluent, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
A kind of preparation method of the pharmaceutical composition for preventing and treating ovarian cyst, it is characterised in that pharmaceutical composition can be using system The conventional method of agent prepares piece agent or capsule or dripping pill.
A kind of preparation method of the pharmaceutical composition for preventing and treating ovarian cyst, it is characterised in that pharmaceutical composition and chemical drugs or Chinese medicine composition prevents and treats ovarian cyst medicine.
It is notable that pharmaceutical composition prevents and treats ovarian cyst effect.
Specific embodiment
Embodiment 1：Prevent and treat pharmaceutical composition of ovarian cyst and preparation method thereof
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of ovarian cyst be：Chinese Lady Fern 4850g three-jaws gold dragon 65g globe amaranth 3600g mesembranone 60g capillarisin 105g alpha, beta-lonones 65g；
Preparation method：
（1）Three-jaw gold dragon, globe amaranth, Chinese Lady Fern, mesembranone, capillarisin, β-violet are taken by bulk drug proportioning Ketone, mixes, and with the ethanol of weight percent concentration 34% as solvent, is taken in 35.5 DEG C of temperature extractions, and extraction time is 8 times, is carried every time The time is taken for 63 hours, each solvent load is 64 times of bulk drug gross weight, and filtration obtains dregs of a decoction A and extract solution A, extract solution A Ethanol is reclaimed, relative density 1.07 is concentrated into, filtered, liquid is first washed with water by H107 large pore resin absorption columns, then with again Amount percent concentration 27% ethanol solution wash-out H107 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 27% Liquid, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 47% as solvent, heating and refluxing extraction 9 times is carried every time The time is taken for 0.4 hour, each solvent load is 35 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.15 is concentrated into, filtered, liquid is first washed with water, then use by GDX-501 large pore resin absorption columns The ethanol solution of weight percent concentration 87% elutes GDX-501 large pore resin absorption columns, collects the ethanol of weight percent concentration 87% Eluent, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 2：Prevent and treat pharmaceutical composition of ovarian cyst and preparation method thereof
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of ovarian cyst be：Chinese Lady Fern 4800g three-jaws gold dragon 80g globe amaranth 3500g mesembranone 70g capillarisin 100g alpha, beta-lonones 70g；
Preparation method：
（1）Three-jaw gold dragon, globe amaranth, Chinese Lady Fern, mesembranone, capillarisin, β-violet are taken by bulk drug proportioning Ketone, mixes, and with the ethanol of weight percent concentration 34% as solvent, is taken in 35.5 DEG C of temperature extractions, and extraction time is 8 times, is carried every time The time is taken for 63 hours, each solvent load is 64 times of bulk drug gross weight, and filtration obtains dregs of a decoction A and extract solution A, extract solution A Ethanol is reclaimed, relative density 1.07 is concentrated into, filtered, liquid is first washed with water by H107 large pore resin absorption columns, then with again Amount percent concentration 27% ethanol solution wash-out H107 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 27% Liquid, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 47% as solvent, heating and refluxing extraction 9 times is carried every time The time is taken for 0.4 hour, each solvent load is 35 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.15 is concentrated into, filtered, liquid is first washed with water, then use by GDX-501 large pore resin absorption columns The ethanol solution of weight percent concentration 87% elutes GDX-501 large pore resin absorption columns, collects the ethanol of weight percent concentration 87% Eluent, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 3：Prevent and treat pharmaceutical composition of ovarian cyst and preparation method thereof
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of ovarian cyst be：Chinese Lady Fern 4900g three-jaws gold dragon 50g globe amaranth 3700g mesembranone 40g capillarisin 110g alpha, beta-lonones 60g；
Preparation method：
（1）Three-jaw gold dragon, globe amaranth, Chinese Lady Fern, mesembranone, capillarisin, β-violet are taken by bulk drug proportioning Ketone, mixes, and with the ethanol of weight percent concentration 34% as solvent, is taken in 35.5 DEG C of temperature extractions, and extraction time is 8 times, is carried every time The time is taken for 63 hours, each solvent load is 64 times of bulk drug gross weight, and filtration obtains dregs of a decoction A and extract solution A, extract solution A Ethanol is reclaimed, relative density 1.07 is concentrated into, filtered, liquid is first washed with water by H107 large pore resin absorption columns, then with again Amount percent concentration 27% ethanol solution wash-out H107 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 27% Liquid, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 47% as solvent, heating and refluxing extraction 9 times is carried every time The time is taken for 0.4 hour, each solvent load is 35 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.15 is concentrated into, filtered, liquid is first washed with water, then use by GDX-501 large pore resin absorption columns The ethanol solution of weight percent concentration 87% elutes GDX-501 large pore resin absorption columns, collects the ethanol of weight percent concentration 87% Eluent, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 4：The preparation of tablet
The pharmaceutical composition 5280g of Example 1, adds starch 5870g, mixes, and granulation is dried, plus microcrystalline cellulose 1540g, Magnesium stearate 18g, mixes, and is pressed into 106000, obtains final product medicinal composition tablets.
Embodiment 5：The preparation of capsule
The pharmaceutical composition 190g of Example 2, adds starch 180g, mixes, and granulation is dried, whole grain, adds appropriate stearic acid Magnesium, mixes, and encapsulated 1300, obtains final product medicament composition capsule.
Embodiment 6：The preparation of dripping pill
Weigh (80 DEG C) heating of Macrogol 6000 235g water-baths and boil molten, add the pharmaceutical composition 13g of embodiment 3, fully stir Mix uniform, with atoleine as cooling agent, put glass tube（4*80cm）In, chilling temperature is 5 DEG C, and drip internal-and external diameter is 7.0/ 2.0 (mm/mm), drip is 2.0cm away from liquid level, and drop speed is optimum condition with every point 49 drop, and the cold of dripping pill surface is blotted with cotton Solidifying agent, obtains final product medicament composition dropping pills.
Experimental example 1：Prevent and treat the experimental study of ovarian cyst
1 data and method
1.1 physical data
It is divided into control group and treatment group according to 50 ovarian cyst patients that random digits table will meet traditional Chinese and western medicine diagnostic criteria, Each 25.21~47 years old control group age；The course of disease 0.6~3 year；Ovarian cyst size 2.4cm × 2.8cm~4.8cm × 6.3cm；Unilateral tumour 22, bilateral tumour 2, chocolate cyst 1.23~48 years old treatment group's age, the course of disease 0.6~ 3 years, tumour size 2.7cm × 2.7cm~5.0cm × 6.2cm；Unilateral tumour 22, bilateral tumour 2, chocolate cyst 1.Two groups of patients have excluded malignant change, and the physical data such as its age, the course of disease, tumour size compares, no statistical difference Meaning (P ＞ 0.05), with comparativity.
1.2 methods
Treatment group：Oral, each 1.1g using pharmaceutical composition (pharmaceutical composition of embodiment 1), 3 times a day, and menstrual period withdraw； And pharmaceutical composition is crushed into wine tune, gauze bag is externally applied to navel and lower abdomen, daily 2 times, continues 30 min, often after steaming It faces the used time and keeps damp a little with wine, and 7d mono- is changed.
Control group：(ShangHai Fudan Fuhua Pharmaceutical Co., Ltd, lot number is 090614 to oral tamoxifen piece, and specification is every The mg of piece 10), each 10mg, daily 2 times, menstrual period withdraw, and with Benzylpenicillin sodium salt, (North China pharmacy share had since menstruation the 1st day Limit company, lot number is E0911149, and specification is every 1,600,000 U) 8,000,000 U add 0.9% sodium chloride injection 250mL veins Instil, Metronidazule injection (Shijiazhuang Siyao Co., Ltd, lot number is 0912017, and specification is every bottle of 100 mL) 200 mL Drip-feed, is used in conjunction 3 d.Two groups with 1 month be 1 course for the treatment of, observe curative effect after 1~3 course for the treatment of, according to curative effect adjust TAM dosage or deactivation.
1.3 curative effect determinate standards
With reference to《New Chinese medicine guideline of clinical investigations》Curative effect is judged.
Cure:Clinical symptom disappearance, gynaecology and color ultrasound examination tumour disappear；
It is effective:Clinical symptoms disappear substantially, and gynaecology and color ultrasound examination tumour reduce more than 2/3；
Effectively:Clinical symptom relief, gynaecology and color ultrasound examination tumour reduce more than 1/3；
It is invalid:Clinical symptoms and tumour size are unchanged.Cure+effective+effectively=total effective.
Ovarian function is represented with estradiol (E2), FSH (FSH).
1.4 statistical procedures
Using the statistical softwares of SPSS 11.0, enumeration data takes Chi-square Test.P ＜ 0.05 are that difference is statistically significant.
2 results
The results are shown in Table 1 and table 2.
1 two groups of patient clinical comparitive studies of table
Group Cure It is effective Effectively It is invalid Total effective rate %
Treatment group（n=25） 12 7 5 1 96.00
Control group（n=25） 6 7 6 6 76.00
Note：Compare with control group, * P<0.05.
E2 and FSH levels compare before and after 2 two groups of patient's treatments of table
Note：With this group before treatment, * P<0.05；Compare with after control group treatment, #P<0.05.

Claims (8)

1. a kind of pharmaceutical composition for preventing and treating ovarian cyst, it is characterised in that be made the bulk drug of the pharmaceutical composition composition and Weight portion is：
Chinese Lady Fern 4800-4900 weight portions three-jaw gold dragon 50-80 weight portion globe amaranth 3500-3700 weight portion pine needles Chrysanthemum alkali 40-70 weight portion capillarisin 100-110 weight portion alpha, beta-lonone 60-70 weight portions.
2. a kind of pharmaceutical composition for preventing and treating ovarian cyst according to claim 1, it is characterised in that be made the drug regimen The composition and weight portion of the bulk drug of thing be：
The weight portion of 3600 weight portion mesembranone of the weight portion three-jaw of the Chinese Lady Fern 4850 imperial 65 weight portion globe amaranth of gold 60 The weight portion of 105 weight portion alpha, beta-lonone of capillarisin 65.
3. a kind of pharmaceutical composition for preventing and treating ovarian cyst according to claim 1, it is characterised in that pharmaceutical composition can be with Piece agent or capsule or dripping pill are prepared using the conventional method of galenic pharmacy.
4. a kind of pharmaceutical composition for preventing and treating ovarian cyst according to claim 1, it is characterised in that pharmaceutical composition with change What medicine or Chinese medicine were constituted prevents and treats ovarian cyst medicine.
5. a kind of preparation method of the pharmaceutical composition for preventing and treating ovarian cyst, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：Chinese Lady Fern 4800-4900 weight portions three-jaw gold dragon 50-80 weight portions thousand days Red 3500-3700 weight portions mesembranone 40-70 weight portions capillarisin 100-110 weight portion alpha, beta-lonones 60-70 Weight portion；
Preparation method：
（1）Three-jaw gold dragon, globe amaranth, Chinese Lady Fern, mesembranone, capillarisin, β-violet are taken by bulk drug proportioning Ketone, mixes, and with the ethanol of weight percent concentration 34% as solvent, is taken in 35.5 DEG C of temperature extractions, and extraction time is 8 times, is carried every time The time is taken for 63 hours, each solvent load is 64 times of bulk drug gross weight, and filtration obtains dregs of a decoction A and extract solution A, extract solution A Ethanol is reclaimed, relative density 1.07 is concentrated into, filtered, liquid is first washed with water by H107 large pore resin absorption columns, then with again Amount percent concentration 27% ethanol solution wash-out H107 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 27% Liquid, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 47% as solvent, heating and refluxing extraction 9 times is carried every time The time is taken for 0.4 hour, each solvent load is 35 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.15 is concentrated into, filtered, liquid is first washed with water, then use by GDX-501 large pore resin absorption columns The ethanol solution of weight percent concentration 87% elutes GDX-501 large pore resin absorption columns, collects the ethanol of weight percent concentration 87% Eluent, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
6. a kind of preparation method of the pharmaceutical composition for preventing and treating ovarian cyst according to claim 5, it is characterised in that by such as It is prepared by lower step：
The composition and weight portion of bulk drug be：The imperial weight of 65 weight portion globe amaranth 3600 of the weight portion three-jaw of Chinese Lady Fern 4850 gold The weight portion of 105 weight portion alpha, beta-lonone of amount part 60 weight portion capillarisin of mesembranone 65；
Preparation method：
（1）Three-jaw gold dragon, globe amaranth, Chinese Lady Fern, mesembranone, capillarisin, β-violet are taken by bulk drug proportioning Ketone, mixes, and with the ethanol of weight percent concentration 34% as solvent, is taken in 35.5 DEG C of temperature extractions, and extraction time is 8 times, is carried every time The time is taken for 63 hours, each solvent load is 64 times of bulk drug gross weight, and filtration obtains dregs of a decoction A and extract solution A, extract solution A Ethanol is reclaimed, relative density 1.07 is concentrated into, filtered, liquid is first washed with water by H107 large pore resin absorption columns, then with again Amount percent concentration 27% ethanol solution wash-out H107 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 27% Liquid, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 47% as solvent, heating and refluxing extraction 9 times is carried every time The time is taken for 0.4 hour, each solvent load is 35 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.15 is concentrated into, filtered, liquid is first washed with water, then use by GDX-501 large pore resin absorption columns The ethanol solution of weight percent concentration 87% elutes GDX-501 large pore resin absorption columns, collects the ethanol of weight percent concentration 87% Eluent, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
7. a kind of preparation method of the pharmaceutical composition for preventing and treating ovarian cyst according to claim 5, it is characterised in that medicine Composition can prepare piece agent or capsule or dripping pill using the conventional method of galenic pharmacy.
8. a kind of preparation method of the pharmaceutical composition for preventing and treating ovarian cyst according to claim 5, it is characterised in that medicine Composition prevents and treats ovarian cyst medicine with chemical drugs or Chinese medicine composition.
CN201611132912.XA 2016-12-10 2016-12-10 A kind of pharmaceutical composition for preventing and treating ovarian cyst Withdrawn CN106822389A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611132912.XA CN106822389A (en) 2016-12-10 2016-12-10 A kind of pharmaceutical composition for preventing and treating ovarian cyst

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611132912.XA CN106822389A (en) 2016-12-10 2016-12-10 A kind of pharmaceutical composition for preventing and treating ovarian cyst

Publications (1)

Publication Number Publication Date
CN106822389A true CN106822389A (en) 2017-06-13

Family

ID=59139077

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611132912.XA Withdrawn CN106822389A (en) 2016-12-10 2016-12-10 A kind of pharmaceutical composition for preventing and treating ovarian cyst

Country Status (1)

Country Link
CN (1) CN106822389A (en)

Similar Documents

Publication Publication Date Title
CN106668348A (en) Pharmaceutical composition for treating diabetic retinopathy
CN106822389A (en) A kind of pharmaceutical composition for preventing and treating ovarian cyst
CN106620056A (en) Pharmaceutical composition for treating diabetic retinopathy
CN106581122A (en) Pharmaceutical composition for treating acute cervicitis
CN105497095A (en) Medicine composition for treating esophagus cancer at middle and late stages
CN106511627A (en) Medicine composition for preventing and treating ovarian cyst
CN106540003A (en) A kind of pharmaceutical composition for treating hyperosteogeny
CN106668546A (en) Pharmaceutical composition for treating ceratitis
CN106074736A (en) A kind of pharmaceutical composition treating cerebral thrombosis and preparation method thereof
CN106727851A (en) Prevent and treat pharmaceutical composition of ovarian cyst and preparation method thereof
CN105535264A (en) Medicine composition for treating senile encephalatrophy
CN105641016A (en) Pharmaceutical composition for treating coronary heart disease
CN106728508A (en) The pharmaceutical composition of anti-treating cervicitis
CN106511642A (en) Pharmaceutical composition preventing diabetic retinopathy and preparation method for pharmaceutical composition
CN106728467A (en) A kind of pharmaceutical composition for preventing and treating climacteric metancholia
CN106539835A (en) A kind of pharmaceutical composition for preventing and treating rhinitis
CN106727874A (en) It is a kind of to prevent and treat pharmaceutical composition of ovarian cyst and preparation method thereof
CN106692376A (en) Pharmaceutical composition for preventing and treating vaginitis
CN106539836A (en) A kind of pharmaceutical composition for treating rhinitis
CN106581263A (en) Pharmaceutical composition for treating lumbar disc herniation and preparation method thereof
CN106692740A (en) Pharmaceutical composition used for treating climacteric syndrome
CN106729027A (en) Pharmaceutical composition for treating climacteric metancholia
CN106727837A (en) Prevent and treat the pharmaceutical composition of rhinitis
CN106822340A (en) A kind of pharmaceutical composition of anti-treating cervicitis
CN106729031A (en) A kind of pharmaceutical composition for treating cold in children

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20170613